Ground‑breaking Phase 3 results for olezarsen in severe hypertriglyceridemia unveiled at AHA Scientific Sessions

Ionis Pharmaceuticals, Inc. has announced pivotal data from its Phase 3 CORE and CORE2 studies of olezarsen in patients with severe hypertriglyceridemia (sHTG). The treatment achieved up to a 72 % placebo‑adjusted mean reduction in fasting triglyceride levels at six months, with the effect sustained through 12 months. Additionally, 86 % of olezarsen‑treated patients reached triglyceride levels below 500 mg/dL — a key threshold for mitigating the risk of acute pancreatitis. Impressively, the study also reported an 85 % reduction in adjudicated acute pancreatitis events compared to placebo. The data were presented as a late‑breaking session at the AHA Scientific Sessions and simultaneously published in the The New England Journal of Medicine. Safety and tolerability of the drug were favourable, with injection‑site reactions being the most common adverse event. Ionis plans to submit a supplemental new drug application for both 50 mg and 80 mg doses of olezarsen by year‑end. #olezarsen #sHTG #cardiometabolichealth #IonisPharma #SlimScan #GrowthStocks #CANSLIM